← Leaderboards
Scott M Rawls
Temple Univ Of The Commonwealth
$11,077,907
Attributed
$13,438,885
Total exposure
16
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,438,885 · 16
By mechanism
R01$6,673,786 · 4
P30$2,186,544 · 2
R21$1,865,533 · 5
R25$1,007,271 · 1
RC1$955,749 · 1
R15$450,000 · 2
Top collaborators
- Ellen M Unterwald6 shared
- Allen B Reitz5 shared
- Sara J. Ward1 shared
Others in their field
Top investigators on “Rattus”
- Barney Sparrow · Battelle Memorial Institute$76,162,078
- Reshan Fernando · Research Triangle Institute$42,714,061
- Boris Tabakoff · University Of Colorado Denver$35,561,072
- Yasmin L Hurd · Icahn School Of Medicine At Mount Sinai$35,063,410
- Milton D Hejtmancik · Battelle Centers/Pub Hlth Res & Evaluatn$34,625,987
- John Damon Chodera · Sloan-Kettering Inst Can Research$33,543,727
Research focus
RattusPharmaceutical PreparationsBrainRewardsPharmacologyBehavioralIn VivoLinkExtracellularSelf AdministrationNucleus AccumbensGlutamatesBaseDependenceCocaineNeurochemistryPre-ClinicalLaboratoriesOpioidAnimal ModelPhysical DependenceWithdrawalIn VitroExposure To
Grant awards (44)
Chemokine Receptor Antagonists (CRAs): Characterization in Preclinical Models of Methamphetamine Use Disorder$552,629
R01 · FY2025 · DA · contact PI
Xylazine effects on methamphetamine-induced behavioral alterations in rats$237,750
R21 · FY2025 · DA · contact PI
Non-beta-lactam GLT-1 activators: characterization in preclinical models of opioid and cocaine addiction$414,677
R01 · FY2024 · DA · contact PI
Component for Institution # 264313$223,133
P30 · FY2024 · DA · contact PI
Kratom and Cannabinoid Constituents: Mechanisms and Interactive Effects in Neuropathic Pain$433,710
R21 · FY2023 · AT
Non-beta-lactam GLT-1 activators: characterization in preclinical models of opioid and cocaine addiction$414,677
R01 · FY2023 · DA · contact PI
Component for Institution # 264313$223,133
P30 · FY2023 · DA · contact PI
Non-beta-lactam GLT-1 activators: characterization in preclinical models of opioid and cocaine addiction$414,677
R01 · FY2022 · DA · contact PI
Chemokine CXCL12/CXCR4 system and synthetic cathinones$368,513
R01 · FY2022 · DA · contact PI
Component for Institution # 264313$223,133
P30 · FY2022 · DA · contact PI
Chemokine CXCL12/CXCR4 system and synthetic cathinones$525,831
R01 · FY2021 · DA · contact PI
Non-beta-lactam GLT-1 activators: characterization in preclinical models of opioid and cocaine addiction$417,646
R01 · FY2021 · DA · contact PI
Component for Institution # 264313$223,133
P30 · FY2021 · DA · contact PI
Non-beta-lactam GLT-1 activators: characterization in preclinical models of opioid and cocaine addiction$455,516
R01 · FY2020 · DA · contact PI
Chemokine CXCL12/CXCR4 system and synthetic cathinones$368,513
R01 · FY2020 · DA · contact PI
Component for Institution # 264313$216,086
P30 · FY2020 · DA · contact PI
Therapeutic secrets of kratom alkaloid mitragynine: Testing efficacy in preclinical neuropathic pain and abuse liability models and characterization of underlying opioid and adrenergic mechanisms$198,125
R21 · FY2020 · AT · contact PI
Chemokine CXCL12/CXCR4 system and synthetic cathinones$158,500
R01 · FY2020 · DA · contact PI
Chemokine CXCL12/CXCR4 system and synthetic cathinones$368,047
R01 · FY2019 · DA · contact PI
Psychoactive bath salts and the glutamate system$366,700
R01 · FY2019 · DA · contact PI
Therapeutic secrets of kratom alkaloid mitragynine: Testing efficacy in preclinical neuropathic pain and abuse liability models and characterization of underlying opioid and adrenergic mechanisms$237,750
R21 · FY2019 · AT · contact PI
Database and Drug Interaction Core$216,325
P30 · FY2019 · DA · contact PI
Chemokine CXCL12/CXCR4 system and synthetic cathinones$381,649
R01 · FY2018 · DA · contact PI
Psychoactive bath salts and the glutamate system$366,700
R01 · FY2018 · DA · contact PI
Trigriluzole for the Treatment of Cocaine Addiction$300,002
R41 · FY2018 · DA · contact PI
Database and Drug Interaction Core$216,325
P30 · FY2018 · DA · contact PI
Psychoactive bath salts and the glutamate system$366,700
R01 · FY2017 · DA · contact PI
Planarians and the pharmacology of addiction: an in vivo model for K-12 education$243,943
R25 · FY2017 · DA · contact PI
Database and Drug Interaction Core$214,791
P30 · FY2017 · DA · contact PI
Psychoactive bath salts and the glutamate system$363,033
R01 · FY2016 · DA · contact PI
Planarians and the pharmacology of addiction: an in vivo model for K-12 education$245,090
R25 · FY2016 · DA · contact PI
Database and Drug Interaction Core$214,161
P30 · FY2016 · DA · contact PI
Psychoactive bath salts and the glutamate system$369,778
R01 · FY2015 · DA · contact PI
Planarians and the pharmacology of addiction: an in vivo model for K-12 education$256,339
R25 · FY2015 · DA · contact PI
Database and Drug Interaction Core$216,324
P30 · FY2015 · DA · contact PI
Planarians and the pharmacology of addiction: an in vivo model for K-12 education$261,899
R25 · FY2014 · DA · contact PI
Mephedrone and addiction: clues from animal models$145,127
R21 · FY2013 · DA · contact PI
Mephedrone and addiction: clues from animal models$192,321
R21 · FY2012 · DA · contact PI
Clavulanic acid: a potential abuse-deterrent and CNS-active therapeutic$191,250
R21 · FY2012 · DA · contact PI
Clavulanic acid: a potential abuse-deterrent and CNS-active therapeutic$229,500
R21 · FY2011 · DA · contact PI
Beta-lactam chemical probes for GLT-1 transporter-related pathologies$477,042
RC1 · FY2010 · DA · contact PI
Beta-lactam chemical probes for GLT-1 transporter-related pathologies$478,707
RC1 · FY2009 · DA · contact PI
Can beta-lactam antibiotics decrease morphine physical dependence?$225,000
R15 · FY2008 · DA · contact PI
Cannabinoid Regulation of Basal Ganglia Glutamate and GABA$225,000
R15 · FY2007 · DA · contact PI